The Le Méridien vaccine (06660) is now up more than 6%. As of press release, it has risen 6.03% to HK$7.91, with a turnover of HK$11.654 million.
The Zhitong Finance App learned that the Emmy vaccine (06660) has now risen by more than 6%. As of press release, it has risen 6.03% to HK$7.91, with a turnover of HK$11.654 million.
According to the news, Emmy Vaccines recently released a number of major R&D product progress announcements, and 3 major iteratively upgraded vaccines have been declared for sale this year. The two major series of iterative upgrades for the pneumonia vaccine and rabies vaccine have been completed, and research and development work is progressing comprehensively, leading the two major golden tracks.
According to the announcement, the company's 13-valent pneumonia conjugate vaccine, serum-free iterative rabies vaccine, and 23-valent pneumopolysaccharide vaccine are undergoing preparations before the new drug is declared and marketed, and plans to complete the marketing declaration within the year. The pneumonia vaccine and rabies vaccine series. In addition to the products that are currently being harvested, the 20-valent pneumococcal conjugate vaccine has submitted pre-clinical trial applications, and the 24-valent pneumonia-conjugate vaccine, which was first developed simultaneously in the world, has completed pre-clinical research work. The novel Technician diploid rabies vaccine is expected to submit a pre-application for clinical trials in the first half of 2024. The world's first mRNA rabies vaccine is the first non-COVID-19 mRNA vaccine product accepted domestically.